

PROGRAM

**Thursday, 27 June 2019**

|  |  |
| --- | --- |
| 16:30 – 16:45​16:45 - 17:15 | **Welcome Address** |
| **Opening Session**​Chairs:**Rifaat Safadi**, *Hadassah Hebrew University, Israel***Quentin Anstee**, *Newcastle University, UK***Keynote Lecture:*** What is NAFLD - NASH and How it is Defined?

**Jean-Francois Dufour**,*University of Bern, Switzerland* |
| ​5 min break |
| ​17:20 – 18:30 | ​**Debate:**Should I be Looking for NASH in My Clinic? PRO**- Jerome Boursier***, Angers University Hospital, France*vs.CON - **Mark Walker***, Newcastle University, UK***Open Discussion and Vote** |
| 18:30 | Networking Reception |

**Friday, 28 June 2019**

|  |  |
| --- | --- |
| 08:00 – 08:30 | Morning Networking |
| 08:30 – 09:00 | **Chair:****Arun Sanyal**, Virginia Commonwealth University, USA**Keynote lecture:*** Biomarkers in NAFLD - If Not a Biopsy, What - and Why?

**Quentin Anstee***, Newcastle University, UK* |
| 09:00 – 11:00   | **Session 1: What Tools Do We Have to Assess Disease Severity in NAFLD****Chair:****Lawrence Serfaty**, University of Strsbourg, France**Blood Tests*** Routine Blood Tests and Simple Scores in NAFLD

**Salvatore Petta***, University of Palermo, Italy** New Technologies: Metabolomics, Genomics & Collagen Biomarkers

**Detlef Schuppan***, Institute of Translational Immunology, Germany***MRI and Ultrasound** * How to Use Imaging to Evaluate NASH in the Clinic – Practical Approaches for Use in the Real World?

**Manuel Romero Gomez***, Institute of Biomedicine of Seville, Spain** Ultrasound-Based Elastography Techniques: TE, ARFI & SSI

**Laurent Castera***, University of Paris-VII, France** MR-Based Assessment of Inflammation and Fibrosis

**Stefan Neubauer***, Oxford University, UK***Panel Discussion - 20 min** |
| 11:00 – 11:30 | Coffee break, Exhibition & Poster Viewing |
| ​11:30 - 12:00 | ​**Keynote Lecture:*** Global Epidemiology & Outcomes of the NAFLD

**Zobair Younossi,***Inova Fairfax Hospital, USA* |
| 12:00 – 13:15          | **Session 2: Screening - How Should I Evaluate NASH in My Clinic?****Chair:****Manuel Romero Gomez**, *Institute of Biomedicine of Seville, Spain***Zobair Younossi,***Inova Fairfax Hospital, USA* **What are the next steps?** Two expert views from different clinical disciplines/settings to cover discussion of key points in the clinical history, how to approach the patient for “global” assessment including liver disease AND wider metabolic disease. What are the warning signs and how would you risk stratify?* Gastro/ Hepatologist Perspective

**Lawrence Serfaty***, University of Strsbourg, France** Diabetоlogist Perspective

**Gianluca Perseghin***, University of Milano-Bicocca, Italy***Case Presentation****Panel Discussion/ QA - 25 min** |
| 13:15 – 14:15 | Lunch, Exhibition & Poster Viewing |
| 14:15 – 15:40         | **Session 3: Treating the Metabolic Syndrome in Patients with NAFLD****Chairs:****Arun Sanyal**, *Virginia Commonwealth University, USA***Gianluca Perseghin**, *University of Milano-Bicocca, Italy** Medical Therapy for T2DM

**Michael Roden***, German Center of Diabetology, Germany** Medical Therapy for Dyslipidaemia

**Dirk Muller-Wieland***, Aachen University Hospital, Germany***Case Presentation:**Optimization of glucose control in a NASH patient with type 2 diabetes**Sabine Kahl**, *German Diabetes Center, Germany***Panel Discussion/QA - 25 min** |
| 15:40 – 16:10 | Coffee Break, Exhibition & Poster Viewing |
| 16:10 – 18:00      | **Session 4: Treating NAFLD in Patients with the Metabolic Syndrome: Current Options****Chairs:****Salvatore Petta,***University of Palermo, Italy***Philip Newsome,***University of Birmingham, UK** Dietary Management

**Shira Zelber Sagi***, Tel Aviv Medical Center, and School of Public oooHealth, the University of Haifa, Israel** Alcohol in NAFLD: An Oxymoron or an Important Cofactor?

      **Philip Newsome***, University of Birmingham, UK** Current Available Pharmacological Therapeutic Options for NAFLD Using Drugs Available Today

**Kris Kowdley***, Swedish Medical Center, USA** Bariatric Surgery for NAFLD

**Sebastian Mueller***, University of Heidelberg, Germany* **Case Presentation**L-liver on O-liver**Yael Milgrom,***Hadassah Hebrew University, Israel***Panel Discussion/QA** |
| 18:00 – 19:30 | Poster presentation & Reception |

**Saturday, 29 June 2019**

|  |  |
| --- | --- |
| 08:00 – 08:30 | Morning Networking |
|    | **Session 5: Therapeutics Horizon Scanning: Treating NAFLD Tomorrow****Chairs:****Michael Roden**, *German Center of Diabetology, Germany***Elisabetta Bugianesi**, *University of Turin, Italy***Keynote Lecture:*** NAFLD Pathophysiology: Targets for Novel Treatments

**Frank Tacke***, Charité University, Berlin, Germany***Drug Targets in Phase 2/3 Trials – Evidence Base and Status Update*** Bile Acid Signaling Pathways (FXR/FGF19)

**Michael Trauner***, Medical University of Vienna, Austria** Metabolic Pathways: Insulin Signaling, PPARs, THRb 2

**Rifaat Safadi**, *Hadassah Hebrew University, Israel** Trials Targeting Fibrosis

**Jörn Schattenberg***, University Medical Center Mainz, Germany***Q&A - 25 min** |
| 10:30 – 11:00 | Coffee Break, Exhibition & Poster Viewing |
| 11:00 - 12:15          | **Session 6: Drug Development Overview & Clinical Pharmacology in Practice****Chairs:****Shira Zelber Sagi**, *Tel Aviv Medical Center, and School of Public Health, the University of Haifa, Israel***Jörn Schattenberg**,*University Medical Center Mainz, Germany***Keynote Lecture:*** Why Too Many Strategies are Failing and do not Continue?

**Arun Sanyal***, Virginia Commonwealth University, USA** DILI in NAFLD: How to Assess if a NASH Drug is Causing Liver Injury

**Guru Aithal***, Nottingham University, UK***Panel Discussion/ QA 25 min** |
| ​12:15 - 13:15 | **​Non-CME industry symposium**(not included in the main event CME/CPD credit offering) |
| 13:15 – 14:15 | Lunch Break, Exhibition & Poster Viewing |
| 14:15 – 16:00  | **Session 7: NAFLD & Malignancy****Chairs:****Stefan Zeuzem**, *Goethe University Hospital, Germany***Frank Tacke**, *Charité University, Berlin, Germany** HCC Surveillance in NAFLD – Who, How and Should You?

**Helen Reeves***, Newcastle University, UK** Extra-Hepatic Malignancies in NAFLD

**Elisabetta Bugianessi***, University of Turin, Italy** Mechanisms of Obesity and NASH Related Carcinogenesis

      **Mathias Heikenwalder*,****German Cancer Research Center, Germany***Case Presentation:**NASH patient with fibrosis F2 that developed HCC. Steatohepatitic variant of hepatocellular carcinoma that has interesting immunohistochemistry analysis and progression**Claudia P Oliveira***, University of Sao Paulo, Brazil***Panel Discussion/QA - 35 min** |
| 16:00 – 16:30 | **Summary & Closing Remarks**  |
|